425 results on '"Liu, Caigang"'
Search Results
2. Camrelizumab plus famitinib in previously chemo-immunotherapy treated patients with advanced NSCLC: results from an open-label multicenter phase 2 basket study
3. FSIP1 enhances the therapeutic sensitivity to CDK4/6 inhibitors in triple-negative breast cancer patients by activating the Nanog pathway
4. CMTM6 overexpression confers trastuzumab resistance in HER2-positive breast cancer
5. KK-LC-1 as a therapeutic target to eliminate ALDH+ stem cells in triple negative breast cancer
6. Polyphenol nanocomplex modulates lactate metabolic reprogramming and elicits immune responses to enhance cancer therapeutic effect
7. KCNJ15 deficiency promotes drug resistance via affecting the function of lysosomes
8. A highly potent small-molecule antagonist of exportin-1 selectively eliminates CD44+CD24- enriched breast cancer stem-like cells
9. A multicentre single arm phase 2 trial of neoadjuvant pyrotinib and letrozole plus dalpiciclib for triple-positive breast cancer
10. DNA mechanical flexibility controls DNA potential to activate cGAS-mediated immune surveillance
11. Targeting SOST using a small-molecule compound retards breast cancer bone metastasis
12. Safety, Efficacy, and Pharmacokinetics of SHR-A1811, a Human Epidermal Growth Factor Receptor 2–Directed Antibody-Drug Conjugate, in Human Epidermal Growth Factor Receptor 2–Expressing or Mutated Advanced Solid Tumors: A Global Phase I Trial.
13. A pilot trial of neoadjuvant pyrotinib plus trastuzumab, dalpiciclib, and letrozole for triple‐positive breast cancer
14. FSIP1 regulates autophagy in breast cancer
15. Author response: Effects of neoadjuvant stereotactic body radiotherapy plus adebrelimab and chemotherapy for triple-negative breast cancer: A pilot study
16. Discovery and biological evaluation of a potent small molecule CRM1 inhibitor for its selective ablation of extranodal NK/T cell lymphoma
17. Author response: Discovery and biological evaluation of a potent small molecule CRM1 inhibitor for its selective ablation of extranodal NK/T cell lymphoma
18. Editor's evaluation: High-content microscopy reveals a morphological signature of bortezomib resistance
19. Efficacy and Safety of neoadjuvant stereotactic body radiotherapy plus adebrelimab and chemotherapy for triple-negative breast cancer: A pilot study
20. FSIP1 binds HER2 directly to regulate breast cancer growth and invasiveness
21. The Global Prevalence of Anxiety Symptoms Among Healthcare Workers Before and During COVID-19: A Systematic Review and Meta-analysis
22. Abstract CT181: A first-in-human (FIH) phase 1 study of SHR-A1921, a TROP-2 targeted antibody-drug conjugate (ADC), in patients with advanced solid tumors
23. Abstract CT175: Safety, tolerability, pharmacokinetics, and antitumor activity of SHR-A1811 in HER2-expressing/mutated advanced solid tumors: A global phase 1, multi-center, first-in-human study
24. Oleic Acid Dissolves cGAS–DNA Phase Separation to Inhibit Immune Surveillance
25. An herbal drug combination identified by knowledge graph alleviates the clinical symptoms of plasma cell mastitis patients: a nonrandomized controlled trial
26. Author response: An herbal drug combination identified by knowledge graph alleviates the clinical symptoms of plasma cell mastitis patients: A nonrandomized controlled trial
27. Efficacy and safety of endocrine therapy after mastectomy in patients with hormone receptor positive breast ductal carcinoma in situ: Retrospective cohort study
28. Surgical Outcomes of Implant-based Breast Reconstruction Using TiLoop Bra Mesh Combined With Pectoralis Major Disconnection
29. Crystal structure of a cytocidal protein from lamprey and its mechanism of action in the selective killing of cancer cells
30. Dalpiciclib partially abrogates ER signaling activation induced by pyrotinib in HER2+HR+ breast cancer
31. The effect of elemene on lung adenocarcinoma A549 cell radiosensitivity and elucidation of its mechanism
32. Author response: Dalpiciclib partially abrogates ER signaling activation induced by pyrotinib in HER2+HR+ breast cancer
33. Author response: Efficacy and safety of endocrine therapy after mastectomy in patients with hormone receptor positive breast ductal carcinoma in situ: Retrospective cohort study
34. Dalpiciclib Partially Abrogates ER Signaling Activation Induced by Pyrotinib In HER2+HR+Breast Cancer
35. Discovery and biological evaluation of a potent small molecule CRM1 inhibitor for its selective ablation of extranodal NK/T cell lymphoma
36. An herbal drug combination identified by knowledge graph alleviates the clinical symptoms of plasma cell mastitis patients: a nonrandomized controlled trial
37. Editor's evaluation: Dysregulation of the PRUNE2/PCA3 genetic axis in human prostate cancer: from experimental discovery to validation in two independent patient cohorts
38. The Analysis of Relevant Gene Networks Based on Driver Genes in Breast Cancer
39. Efficacy and safety of endocrine therapy after mastectomy in patients with hormone receptor positive breast ductal carcinoma in situ:retrospective cohort study
40. Editor's evaluation: Machine learning-assisted elucidation of CD81–CD44 interactions in promoting cancer stemness and extracellular vesicle integrity
41. Characteristics and survival in bone metastatic breast cancer patients with different hormone receptor status: A population-based cohort study
42. Cohort Profile: The Northeast China Biobank (NEC-Biobank)
43. Editor's evaluation: Early stage NSCLS patients’ prognostic prediction with multi-information using transformer and graph neural network model
44. KK-LC-1 as a therapeutic target to eliminate ALDH+ stem cells in triple negative breast cancer.
45. Improvements to the gastric cancer tumor-node-metastasis staging system based on computer-aided unsupervised clustering
46. The expression of stem cell protein Piwil2 and piR-932 in breast cancer
47. Editor's evaluation: VPS9D1-AS1 overexpression amplifies intratumoral TGF-β signaling and promotes tumor cell escape from CD8+ T cell killing in colorectal cancer
48. CPGJ602 plus mFOLFOX6 as first-line treatment for patients with KRAS/NRAS/BRAF wild-type metastatic colorectal cancer: A randomized phase II study.
49. Primary analysis of MUKDEN 01: A multicenter, single-arm, prospective, phase 2 study of neoadjuvant treatment with pyrotinib and letrozole plus dalpiciclib in triple-positive breast cancer.
50. Corrigendum: Downregulation of GLYAT Facilitates Tumor Growth and Metastasis and Poor Clinical Outcomes Through the PI3K/AKT/Snail Pathway in Human Breast Cancer
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.